UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

The liver pharmacological and xenobiotic gene response repertoire

Molecular systems biology, 2008, Vol.4 (1), p.175-n/a

2008

Volltextzugriff (PDF)

821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A919-A919

2023

Volltextzugriff (PDF)

Classification of a large microarray data set: algorithm comparison and analysis of drug signatures

Genome research, 2005-05, Vol.15 (5), p.724

2005

Volltextzugriff (PDF)

NSAID-Induced Acute Phase Response is Due to Increased Intestinal Permeability and Characterized by Early and Consistent Alterations in Hepatic Gene Expression

Toxicologic pathology, 2006-01, Vol.34 (2), p.168-179

2006

Volltextzugriff (PDF)

A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11

Proceedings of the National Academy of Sciences - PNAS, 1999-01, Vol.96 (1), p.197-202

1999

Volltextzugriff (PDF)

Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1559-1559

2019

Volltextzugriff (PDF)

Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action

Journal of biotechnology, 2005-09, Vol.119 (3), p.219-244

2005

Volltextzugriff (PDF)

Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2964-2964

2023

Volltextzugriff (PDF)

Minimum Structural Requirements for Peptide Presentation by Major Histocompatibility Complex Class II Molecules: Implications in Induction of Autoimmunity

Proceedings of the National Academy of Sciences - PNAS, 1994-01, Vol.91 (2), p.767-771

1994

Volltextzugriff (PDF)

Abstract 2911: The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2911-2911

2022

Volltextzugriff (PDF)

A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis

The Journal of experimental medicine, 1992-08, Vol.176 (2), p.605-609

1992

Volltextzugriff (PDF)

A small number of residues in the class II molecule I-A u confer the ability to bind the myelin basic protein peptide Ac1-11

Proceedings of the National Academy of Sciences - PNAS, 1999-01, Vol.96 (1), p.197-202

1999

Volltextzugriff (PDF)

A Small Number of Residues in the Class II Molecule I-AuConfer the Ability to Bind the Myelin Basic Protein Peptide Ac1-11

Proceedings of the National Academy of Sciences - PNAS, 1999-01, Vol.96 (1), p.197-202

1999

Volltextzugriff (PDF)

High-Dose Soluble Antigen: Peripheral T-Cell Proliferation or Apoptosis

Immunological reviews, 1994-12, Vol.142 (1), p.193-208

1994

Volltextzugriff (PDF)

Induction of hypoxia in glass versus Permanox petri dishes

Radiation research, 1990-04, Vol.122 (1), p.72

1990

Volltextzugriff (PDF)

605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A640-A640

2020

Volltextzugriff (PDF)

784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A819-A819

2021

Volltextzugriff (PDF)

603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A638-A638

2020

Volltextzugriff (PDF)

Positron emission tomography and stage migration for head and neck cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.6018-6018

2013

Volltextzugriff (PDF)

Early intervention in low-birth-weight premature infants. Results through age 5 years from the Infant Health and Development Program

JAMA : the journal of the American Medical Association, 1994-10, Vol.272 (16), p.1257

1994

Volltextzugriff (PDF)

Preclinical drug safety analysis by chemogenomic profiling in the liver

American journal of pharmacogenomics, 2005, Vol.5 (3), p.161-171

2005

Volltextzugriff (PDF)

Binding of an Invariant-Chain Peptide, CLIP, to I-A Major Histocompatibility Complex Class II Molecules

Proceedings of the National Academy of Sciences - PNAS, 1995-01, Vol.92 (1), p.335-339

1995

Volltextzugriff (PDF)

Chemogenomics – pharmacology with genomics tools

Targets, 2002, Vol.1 (2), p.59-65

2002

Volltextzugriff (PDF)

Diego Rivera's artistic journey

Pearson, Mary Cecelia

2000

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(22)

Publikationsform

Sprache

Englisch
(29)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Animals
(13)
Science & Technology
(10)
Life Sciences & Biomedicine
(8)
Biological And Medical Sciences
(6)
Immunotherapy
(5)
Mice
(5)
Amino Acid Sequence
(4)
Antibodies
(4)
Gene Expression
(4)
Liver - Drug Effects
(4)
Liver - Metabolism
(4)
Molecular Sequence Data
(4)
Myelin Basic Protein - Immunology
(4)
Rats
(4)
T-Lymphocytes - Immunology
(4)
Tumors
(4)
Amino Acids
(3)
Cell Lines
(3)
Dose-Response Relationship, Drug
(3)
Fundamental And Applied Biological Sciences. Psychology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The liver pharmacological and xenobiotic gene response repertoire

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab

Classification of a large microarray data set: algorithm comparison and analysis of drug signatures

NSAID-Induced Acute Phase Response is Due to Increased Intestinal Permeability and Characterized by Early and Consistent Alterations in Hepatic Gene Expression

A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11

Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models

Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action

Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042

Minimum Structural Requirements for Peptide Presentation by Major Histocompatibility Complex Class II Molecules: Implications in Induction of Autoimmunity

Abstract 2911: The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming

A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis

A small number of residues in the class II molecule I-A u confer the ability to bind the myelin basic protein peptide Ac1-11

A Small Number of Residues in the Class II Molecule I-AuConfer the Ability to Bind the Myelin Basic Protein Peptide Ac1-11

High-Dose Soluble Antigen: Peripheral T-Cell Proliferation or Apoptosis

Induction of hypoxia in glass versus Permanox petri dishes

605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors

603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration

Positron emission tomography and stage migration for head and neck cancer

Early intervention in low-birth-weight premature infants. Results through age 5 years from the Infant Health and Development Program

Preclinical drug safety analysis by chemogenomic profiling in the liver

Binding of an Invariant-Chain Peptide, CLIP, to I-A Major Histocompatibility Complex Class II Molecules

Chemogenomics – pharmacology with genomics tools

Diego Rivera's artistic journey

Suchergebnisse filtern